Novel pro-atherogenic molecule coupling factor 6 is elevated in patients with stroke: A possible linkage to homocysteine

作者：Osanai Tomohiro^*; Fujiwara Naoto; Sasaki Satoko; Metoki Norifumi; Saitoh Genta; Tomita Hirofumi; Nishimura Takashi; Shibutani Shuji; Yokoyama Hiroaki; Konta Yoshiyuki; Magota Koji; Okumura Ken

来源：Annals of Medicine, 2010, 42(1): 79-86.

DOI：10.3109/07853890903451781

• Atherosclerosis
• coupling factor 6
• homocysteine
• stroke
• vitamin

Background and purpose. Homocysteine (Hcy) is an independent predictor of stroke. Coupling factor 6 (CF6) is regulated by nuclear factor kappa B (NF-kappa B) signaling which is activated by Hcy. We tested the hypothesis that CF6 is elevated with Hcy in stroke. We also examined the effect of vitamin treatment on CF6 and Hcy levels.
Methods and results. The 59 Japanese patients with a recent history of stroke were randomly assigned to a group without vitamin treatment (Group 1, n = 29) and to a group with treatment with both folic acid and vitamin B(12) for 2 months (Group 2, n = 30). The CF6 level was elevated in the patients with stroke compared with that in controls (n = 64) at admission. In a multiple regression model, the plasma CF6 level was weakly correlated to the total Hcy (tHcy) level. In Group 1, the plasma tHcy and CF6 levels were unchanged. In Group 2, however, they were both decreased, and there was a weak positive correlation between the decreases in plasma levels of CF6 and tHcy.
Conclusion. CF6 is elevated in patients with stroke independently of risk factors. Since Hcy and vitamin treatment affect CF6 levels in stroke, CF6 appears to be a novel molecule for the pathogenesis and treatment of stroke.

• 出版日期2010-2